WO2024095057 - RFID-ENABLED MEDICAL INJECTORS AND ARTIFICIAL INTELLIGENCE (AI) PLATFORM FOR PRE-INJECTION INTERROGATION
National phase entry is expected:
Publication Number
WO/2024/095057
Publication Date
10.05.2024
International Application No.
PCT/IB2023/000651
International Filing Date
06.11.2023
Title **
[English]
RFID-ENABLED MEDICAL INJECTORS AND ARTIFICIAL INTELLIGENCE (AI) PLATFORM FOR PRE-INJECTION INTERROGATION
[French]
INJECTEURS MÉDICAUX ACTIVÉS PAR RFID ET PLATEFORME D'INTELLIGENCE ARTIFICIELLE (IA) POUR INTERROGATION DE PRÉ-INJECTION
Applicants **
KOSKA FAMILY LIMITED
Inventors
WALKER, Jay, S.
Priority Data
63/423,041
06.11.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2046 | |
| EPO | Filing, Examination, Granting | 8743 | |
| Japan | Filing, Examination, Granting | 1961 | |
| South Korea | Filing, Examination, Granting | 1614 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
19,104
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
In some embodiments, an Al agent may be operable to conduct a pre-injection interview with a patient (e.g., as part of a self-injection process) prior to authorizing an injection for the patient. The interrogation may be designed to identify whether the patient is at an increased risk of adverse side effects, based on historical data accessible to the Al agent. In accordance with some embodiments, the Al agent may be programmed to learn and improve the questions to ask patient (e.g., for a given fluid agent, in particular circumstances, for specific types of questions, or otherwise), based on inputs received from patients who have previously received injections and experienced adverse side effects. In some embodiments, the Al agent may further be programmed to implement one or more mitigation measures based on a result of such an interrogation.[French]
Dans certains modes de réalisation, un agent d'IA peut être utilisé pour réaliser un entretien de pré-injection avec un patient (par exemple, en tant que partie d'un processus d'auto-injection) avant d'autoriser une injection pour le patient. L'interrogation peut être conçue pour identifier si le patient présente un risque accru d'effets secondaires indésirables, sur la base de données historiques accessibles à l'agent d'IA. Selon certains modes de réalisation, l'agent d'IA peut être programmé pour apprendre et améliorer les questions à poser à un patient (par exemple, pour un agent fluide donné, dans des circonstances particulières, pour des types spécifiques de questions, ou autrement), sur la base d'entrées reçues en provenance de patients qui ont reçu précédemment des injections et ont subi des effets secondaires indésirables. Dans certains modes de réalisation, l'agent d'IA peut en outre être programmé pour mettre en œuvre une ou plusieurs mesures d'atténuation sur la base d'un résultat d'une telle interrogation.